Damora Therapeutics, Inc.NASDAQ: DMRA

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

· Issued by Damora Therapeutics, Inc.

Summary by 6ix AI

Damora Therapeutics, a biotechnology company focused on blood disorders, granted options to buy an aggregate of 144,400 Damora ordinary shares to five newly-hired, non-executive employees on October 1, 2026, as inducements to accept employment under Nasdaq Listing Rule 5635(4).

Key details

  • The options have a 10-year term and an exercise price of $21.28 per share.
  • 25% of the options vest on the first anniversary of each employee's start date, with the rest vesting in equal monthly installments over the following 36 months.
  • The grants were approved by the independent Compensation Committee of Damora's Board of Directors.
  • The grants are subject to the terms of the 2022 Damora Therapeutics, Inc. Inducement Plan and an option award agreement.

6ix AI wrote this summary from the release below and checked it against the release.

BOSTON - Damora Therapeutics, Inc. (NASDAQ: DMRA) ('Damora'), a biotechnology company working to fundamentally redefine care for patients with blood disorders, announced that it granted equity awards to five newly-hired, non-executive employees on October 1, 2026.

The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(4).

The inducement grants consist of options to purchase an aggregate of 144,400 Damora ordinary shares with a 10-year term and an exercise price of $21.28 per share. All of the options vest as to 25% on the first anniversary of the employees' start date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of an option award agreement.

About Damora Therapeutics

Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes.

Contact:

Jim Baker

Email: [email protected]

(C) 2026 Electronic News Publishing, source ENP Newswire

Damora Therapeutics, Inc. on 6ix

Story so far

Earlier from Damora Therapeutics

Later from Damora Therapeutics

All Damora Therapeutics news releases